Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis

The primary efficacy outcome in trials of urate lowering therapy (ULT) for gout is serum urate (SU). The aim of this study was to examine the strength of the relationship between SU and patient-important outcomes to determine whether SU is an adequate surrogate endpoint for clinical trials.

Source: Seminars in Arthritis and Rheumatism - February 20, 2018 Category: Rheumatology Authors: Lisa Stamp, Melanie B. Morillon, William J. Taylor, Nicola Dalbeth, Jasvinder A. Singh, Marissa Lassere, Robin Christensen Source Type: research